TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27880086
Drug: Calendula officinalis
Normalized name: Calendula officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calendula officinalis vaginal cream
Study: 22089378
Drug: etravirine in
Normalized name: Product containing etravirine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine in combination with darunavir/ritonavir
Study: 19389246
Drug: Cognitive‐behaviour therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behaviour therapy (10 weekly sessions)
Study: 19389246
Drug: Recommended pharmacological
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended pharmacological treatment (pregabalin 300‐600 mg/day, with duloxetine 60‐120 mg/day if comorbid depression)
Study: 19389246
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment at primary care level
Study: 17244133
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health visit (OHV) invitation
Study: 15837982
Drug: AC-DOC (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-DOC (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 21 days followed by docetaxel 100 mg/m2 every 21 days for four cycles)
Study: 15837982
Drug: ADOC (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADOC (doxorubicin 50 mg/m2 plus docetaxel 75 mg/m2 every 14 days for four cycles with filgrastim support)
Study: 28639987
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy
Study: 7836705
Drug: Thymopentin therapy
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin therapy for 6 months
Study: 27196574
Drug: ibodutant 10
Normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibodutant 10 mg
Study: 27196574
Drug: ibodutant 1
Normalized name: Ibodutant
DrugBank: Ibodutant (DB12042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibodutant 1 mg, 3 mg, 10 mg
Study: 27196574
Drug: ibodutant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibodutant (all doses)
Study: 23810109
Drug: Low-volume, energy-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume, energy- and nutrient-dense oral nutritional supplement (ONS) 2 × 125 mL (600 kcal, 24 g protein) per day
Study: 25104835
Drug: Exposure-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive-behavioural therapy (CBT) for 12 weeks
Study: 17284861
Drug: CSNs10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSNs10 (10 mg/kg of capsinoids)
Study: 17284861
Drug: CSNs3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSNs3 (3 mg/kg of capsinoids)
Study: 12399272
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPA/d for 6 weeks
Study: 12399272
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g DHA/d for 6 weeks
Study: 7595709
Drug: Paclitaxel via
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel via 3-hour infusion at a starting dose of 250 mg/m2 for group I and 175 mg/m2 for group II.
Study: 7595709
Drug: Paclitaxel via
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel via 3-hour infusion without prophylactic G-CSF.
Study: 7027924
Drug: Cefoxitin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1-g preoperative bolus)
Study: 7027924
Drug: Cephalothin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (1-g preoperative dose)
Study: 27911471
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg CoQ10 supplements per day for 12 weeks
Study: 24142232
Drug: M72/AS01B (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01B (40 μg)
Study: 24142232
Drug: M72/AS01E (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01E (10 μg)
Study: 24142232
Drug: M72/AS01E (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS01E (20 μg)
Study: 24142232
Drug: M72/AS02D (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/AS02D (10 μg)
Study: 24142232
Drug: M72/Saline (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: M72/Saline (40 μg)
Study: 22052267
Drug: 0.1% hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hyaluronan formulations of different molecular weights (50, 130, 300, 800 and 2000 kDa) applied twice-daily for 60 days
Study: 22052267
Drug: 0.1% hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hyaluronan formulations (specifically 130 and 50 kDa)
Study: 18452433
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control cream applied to the other eye
Study: 16679433
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with disease-modifying antirheumatic drugs (DMARDs)
Study: 16679433
Drug: Delayed start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed start with disease-modifying antirheumatic drugs (DMARDs)
Study: 16253583
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin
Study: 15531933
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin and 25 mg of rofecoxib
Study: 8400345
Drug: MPA/PVP formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA/PVP formulation (200 mg sachet)
Study: 8400345
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation (500 mg tablet)
Study: 3461726
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg/butalbital 50 mg/caffeine 40 mg/codeine 30 mg
Study: 3461726
Drug: Acetaminophen 300
Normalized name: acetaminophen 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 300 mg/codeine 30 mg
Study: 31061718
Drug: Augmented Depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Depression Therapy (ADepT) - 15 weekly acute sessions and 5 booster sessions in the following year
Study: 31061718
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) - 20 weekly acute sessions
Study: 29024304
Drug: Alprostadil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (20 ug/day, intravenous administration diluted with 100 ml normal saline, from 0.5 to 1 hr before to 3 days after operation)
Study: 29024304
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hydration therapy only)
Study: 24857532
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (eight 90-minute sessions)
Study: 22661182
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 μg/kg 1 min before administration of fentanyl 2 μg/kg (Group II)
Study: 22661182
Drug: Fentanyl 2.5
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2.5 μg/kg (Group I)
Study: 22661182
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 μg/kg 1 min before administration of fentanyl 1.5 μg/kg (Group III)
Study: 22661182
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 μg/kg 1 min before administration of fentanyl 1 μg/kg (Group IV)
Study: 17692643
Drug: Continuous fenoldopam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous fenoldopam infusion (0.06 mcg/kg per minute)
Study: 9598780
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg
Study: 9842977
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg
Study: 9598780
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 500 mg
Study: 2651332
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of Tisacid (acid‐neutralizing capacity = 78 mmol)
Study: 2651332
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of Tisacid (acid‐neutralizing capacity = 156 mmol)
Study: 2651332
Drug: 12 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g/day of Tisacid (acid‐neutralizing capacity = 312 mmol)
Study: 2651332
Drug: 1.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/day cimetidine (control)
Study: 138654
Drug: Terracortril ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terracortril ointment or cream
Study: 30545717
Drug: Chloroquine as
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine as weekly chemoprophylaxis
Study: 30545717
Drug: Chloroquine as
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine as intermittent treatment
Study: 24732671
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 200 μg
Study: 24732671
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 100 μg
Study: 24021303
Drug: CJ‐50300 smallpox
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJ‐50300 smallpox vaccine administered with a bifurcated needle over the deltoid muscle.
Study: 21721072
Drug: Weekly assessment
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly assessment
Study: 19555036
Drug: Nebivolol (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5.0 mg/day)
Study: 19555036
Drug: Ivabradin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradin (mean dose 7.5 mg)
Study: 19555036
Drug: Basic combined
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic combined therapy (ACE inhibitors, diuretics, aspirin, statins, on demand nitrates)
Study: 10187933
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride spray (group II)
Study: 8800725
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution (group II, n = 100)
Study: 8800725
Drug: Stanford solution
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stanford solution (group I, n = 95)
Study: 313148
Drug: Crossover from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover from medical to surgical therapy
Study: 31324199
Drug: Sanjin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjin tablets plus levofloxacin tablets placebo
Study: 31324199
Drug: Levofloxacin tablets
Normalized name: Levofloxacin Tablets
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin tablets plus Sanjin tablets placebo
Study: 31324199
Drug: Sanjin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjin tablets plus levofloxacin tablets
Study: 16048569
Drug: Large volume
Normalized name: NEBULIZER,LARGE VOLUME #1770
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large volume paracentesis (LVP) with intravenous albumin
Study: 16048569
Drug: Diuretics with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics with intravenous albumin
Study: 11930101
Drug: Cimetropium bromide
Normalized name: cimetropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetropium bromide (1.2 mg/kg)
Study: 8597003
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 200 mg 4-hourly
Study: 8597003
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 125 mg 12-hourly
Study: 2132290
Drug: morniflumate (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: morniflumate (700 mg tablet twice a day) + amoxicillin (1 g tablet twice a day)
Study: 2132290
Drug: feprazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: feprazone (200 mg tablet twice a day) + amoxicillin (1 g tablet twice a day)
Study: 2132290
Drug: amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin (1 g tablet twice a day)
Study: 500516
Drug: GENT alone
Normalized name: Gent-L-Tip
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GENT alone at a dose of 1.5 mg/kg/8 hourly
Study: 500516
Drug: GENT +
Normalized name: Gent-L-Tip
DrugBank: Sodium phosphate, dibasic, unspecified form (DB14504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GENT + CTIN at a dose of 2 g or 3 g 8 hourly by i.v. bolus
Study: 28086181
Drug: Brief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief treatment
Study: 25431429
Drug: Social recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social recovery cognitive-behavioural therapy (SRCBT)
Study: 23595562
Drug: Raloxifene (RLX)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (RLX) 60 mg
Study: 17845921
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day) for 4 weeks
Study: 17845921
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg/day) for 4 weeks
Study: 14743356
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen
Study: 9670269
Drug: Isolated hyperthermic
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated hyperthermic liver perfusion (IHLP) with anticancer agents
Study: 7920751
Drug: Decapeptyl (D‐Trp6‐LHRH)
Normalized name: (D-Trp6)-GnRH
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decapeptyl (D‐Trp6‐LHRH) depot 3.2 mg for 3‐6 months + conservative myomectomy
Study: 7920751
Drug: Decapeptyl (D‐Trp6‐LHRH)
Normalized name: (D-Trp6)-GnRH
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decapeptyl (D‐Trp6‐LHRH) depot 3.2 mg for 3‐6 months without myomectomy
Study: 31525444
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of concentrated water-in-oil emulsions
Study: 31525444
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of concentrated water-in-oil emulsions with isopropyl myristate
Study: 31525444
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of concentrated water-in-oil emulsions with liquid paraffin
Study: 29098783
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS), 20 g/day
Study: 29098783
Drug: Control iron/folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control iron/folic acid (IFA) tablet
Study: 24274259
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily for 3 months
Study: 17934422
Drug: Guidelines for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines for management of patients on oral anticoagulants
Study: 16278591
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human atrial natriuretic peptide infusion (Group H: n=19)
Study: 16278591
Drug: Conventional diuretics
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diuretics (furosemide and potassium canrenoate) (Group C: n=18)
Study: 10549465
Drug: Prochlorperazine buccal
Normalized name: prochlorperazine Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine buccal 6 mg
Study: 7768761
Drug: Meropenem, 500
Normalized name: Meropenem, 500 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem, 500 mg q 8 h
Study: 7768761
Drug: Imipenem/cilastatin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin, 500 mg/500 mg q 8 h
Study: 378561
Drug: Undecylenic acid
Normalized name: Undecylenic Acid
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undecylenic acid ointment
Study: 1096122
Drug: Tolnaftate cream
Normalized name: Tolnaftate Cream
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolnaftate cream
Study: 378561
Drug: Undecylenic acid
Normalized name: Undecylenic Acid
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undecylenic acid ointment and Tolnaftate cream
Study: 31687953
Drug: Antiseptic solution
Normalized name: ANTISEPTIC SOLUTION
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiseptic solution 'Decasan', probiotic 'BioGaia ProDentis', immune modulator 'Imupret'
Study: 20113411
Drug: Control patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patch
Study: 24326693
Drug: Droxidopa (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (100-600 mg t.i.d.)
Study: 17974866
Drug: No anti-Alzheimer
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-Alzheimer drugs
Study: 16280656
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate glycine lozenges
Study: 31549625
Drug: bococizumab 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bococizumab 50, 100, or 150 mg
Study: 6714903
Drug: Antacid A
Normalized name: Antacid Anti-Gas
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid A (high magnesium content)
Study: 6714903
Drug: Al-Ca-antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Ca-antacid
Study: 6714903
Drug: Antacid B
Normalized name: Maalox Antacid Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid B (lower magnesium content)
Study: 6714903
Drug: Triple-combination (Al,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination (Al, Mg, Ca)
Study: 6714903
Drug: Al-Ca-antacid and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Ca-antacid and Al-Mg-Ca-antacid
Study: 31152977
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg (single oral dose)
Study: 16401957
Drug: Opiate antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Opiate antagonist detoxification under general anesthesia
Study: 10651701
Drug: terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine 250 mg daily for 12 weeks
Study: 10651701
Drug: fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluconazole 150 mg once weekly for 12 weeks
Study: 10651701
Drug: fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluconazole 150 mg once weekly for 24 weeks
Study: 8885738
Drug: Supine position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supine position after epidural injection
Study: 28790547
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg in the morning for 28 days, analgesic (diclofenac 75 mg), high fluid intake
Study: 28790547
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received analgesic (diclofenac 75 mg), high fluid intake
Study: 23642125
Drug: Dexamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (12 mg administered in two syringes, 24 hours apart)
Study: 23642125
Drug: Betamethasone (11.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (11.4 mg administered in two syringes, 24 hours apart)
Study: 21112155
Drug: Acamprosate 666
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 666 mg three times daily
Study: 19623836
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic prophylaxis (cephalexin, gentamycin, cephazolin)
Study: 8622022
Drug: CMF-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF-based adjuvant chemotherapy
Study: 7848882
Drug: Local-regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local-regional treatment alone
Study: 7848882
Drug: CMF-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF-based chemotherapy
Study: 2908133
Drug: Ketazolam 15
Normalized name: ketazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketazolam 15 mg
Study: 26610167
Drug: Dialogical Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialogical Exposure Therapy (DET)
Study: 27817180
Drug: Self-Administered Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administered Stress Management Training (SSMT)
Study: 27817180
Drug: SSMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSMT with psychotropic agent
Study: 21150199
Drug: Topical methylprednisolone
Normalized name: methylprednisolone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methylprednisolone applied to the round window during cochlear implantation
Study: 21150199
Drug: Topical methylprednisolone
Normalized name: methylprednisolone Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methylprednisolone